Investors need to pay close attention to Catalent (CTLT) stock based on the movements in the options market lately.

Catalent (CTLT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a ...

Increased demand for biologics and biosimilars is driving the demand for dual chamber prefilled syringes.Rockville, MD, Sept.

On Thursday, Catalent Inc (CTLT) stock saw a decline, ending the day at $60.4 which represents a decrease of $-0.32 or -0.53% from the prior close of $60.72. The stock opened at $60.7 and touched a ...

Aug 29 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment that develops and ...

A contract manufacturing drug organization executive said he believes that Novo Nordisk's (NVO) planned purchase of Catalent (NYSE:CTLT) will spur competition. Beau Garrett, CEO of American ...

(Reuters) - Catalent said on Friday it was unable to file its annual report with regulators on time as it requires additional ...

Aug 30 (Reuters) - Catalent (CTLT.N), opens new tab said on Friday it was unable to file its annual report with regulators on time as it requires additional time to complete "certain processes".

Catalent Inc (CTLT) stock saw a decline, ending the day at $60.7 which represents a decrease of $-0.26 or -0.43% from the prior close of $60.96. The stock opened at $60.6 and touched a low of $60.49 ...